Holen Sie sich die Stockscreener-App
9.94
6.54%
0.61
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.06m - simplywall.st
Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha
More C-suite changes at Dyne - biocentury.com
Dyne Therapeutics reshapes leadership team ahead of drug launches By Investing.com - Investing.com South Africa
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Enhances Leadership Team with Key Appoin - GuruFocus
Dyne Therapeutics Announces Chief Business Officer and Chief Sci - GuruFocus
Dyne Therapeutics reshapes leadership team ahead of drug launches - Investing.com
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments - GlobeNewswire
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dyne Therapeutics Reveals Strategic Compensation Plan: 330K Stock Options Granted - Stock Titan
Dyne wins new Outperform at BMO on prospects for lead drug - MSN
Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m - Yahoo
Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com
RBC Cuts Price Target on Dyne Therapeutics to $36 From $41, Keeps Outperform, Speculative Risk - MarketScreener
FORCE platform boosts muscle function in dystrophic mice - BioWorld MedTech
Oversold Conditions For Dyne Therapeutics - Nasdaq
FORCE platform leads to Duchenne muscular dystrophy mouse model - BioWorld MedTech
BMO maintains Dyne Therapeutics stock with $50 target By Investing.com - Investing.com Canada
MDA 2025: DYNE-101 improves finger function in DM1 clinical trial - Muscular Dystrophy News
Dyne names Editas’ Erick Lucera CFO - BioCentury
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path - Benzinga
Sector Update: Health Care Stocks Steady Premarket Friday -March 21, 2025 at 09:24 am EDT - Marketscreener.com
JPMorgan cuts Dyne Therapeutics stock target to $17 from $18 By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer - The National Law Review
Dyne Therapeutics Appoints Erick Lucera as Chief Financial Officer - citybiz
Dyne Therapeutics names new CFO ahead of clinical milestones By Investing.com - Investing.com South Africa
Dyne Therapeutics Names Erick Lucera as CFO -March 20, 2025 at 05:36 pm EDT - Marketscreener.com
Dyne Therapeutics Appoints Erick Lucera as CFO - TipRanks
Dyne Therapeutics Announces Appointment of Erick J. Lucera As Chief Financial Officer - Marketscreener.com
Dyne Therapeutics names new CFO ahead of clinical milestones - Investing.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq - GlobeNewswire
New Dyne Therapeutics CFO Secures Major Equity Package Worth 280,600 Shares - StockTitan
Dyne Therapeutics Strengthens Commercial Launch Plans With Strategic CFO Appointment - StockTitan
(DYN) Technical Data - news.stocktradersdaily.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer - The Globe and Mail
Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251 - MSN
Stifel maintains Buy on Dyne Therapeutics with $66 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock - Investing.com
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results - MarketScreener
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank - The Globe and Mail
Dyne Therapeutics Announces New Long-Term Clinical Data - GlobeNewswire
Dyne : Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months - Nasdaq
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - The Manila Times
Dyne Therapeutics Reports Promising Long-Term Data for DYNE-251 in Duchenne Muscular Dystrophy with Plans for Accelerated Approval Submission - Nasdaq
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World
Dyne therapeutics chief commercial officer sells $1,733 in stock By Investing.com - Investing.com India
BMO Capital Markets Begins Coverage on Dyne Therapeutics (NASDAQ:DYN) - Defense World
Dyne therapeutics chief commercial officer sells $1,733 in stock - Investing.com
Dyne Therapeutics chief scientific officer sells shares worth $24,501 By Investing.com - Investing.com South Africa
1.75%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):